Trinity Biotech (NASDAQ: TRIB) is one of 25 publicly-traded companies in the “Diagnostic substances” industry, but how does it weigh in compared to its rivals? We will compare Trinity Biotech to related businesses based on the strength of its dividends, earnings, profitability, valuation, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Trinity Biotech and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Trinity Biotech -40.62% 2.37% 0.99%
Trinity Biotech Competitors -583.73% -65.87% -25.47%

Institutional and Insider Ownership

62.1% of Trinity Biotech shares are held by institutional investors. Comparatively, 52.1% of shares of all “Diagnostic substances” companies are held by institutional investors. 8.2% of Trinity Biotech shares are held by insiders. Comparatively, 12.7% of shares of all “Diagnostic substances” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Trinity Biotech and its rivals gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Trinity Biotech $99.14 million $2.30 million 18.50
Trinity Biotech Competitors $308.36 million $13.11 million -43.37

Trinity Biotech’s rivals have higher revenue and earnings than Trinity Biotech. Trinity Biotech is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Trinity Biotech has a beta of 1.31, indicating that its stock price is 31% more volatile than the S&P 500. Comparatively, Trinity Biotech’s rivals have a beta of 1.44, indicating that their average stock price is 44% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Trinity Biotech and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Trinity Biotech 0 0 0 0 N/A
Trinity Biotech Competitors 102 376 573 19 2.48

As a group, “Diagnostic substances” companies have a potential upside of 10.12%. Given Trinity Biotech’s rivals higher possible upside, analysts plainly believe Trinity Biotech has less favorable growth aspects than its rivals.

About Trinity Biotech

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease, sexually transmitted diseases, respiratory infections, epstein barr virus, and other viral pathogens; and products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a high risk of developing diabetes. It also develops, manufactures, and distributes products in the enzyme-linked immunosorbent, western blot, and cytotoxicity assay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. Further, it offers Uni-Gold S. pneumoniae, Uni-Gold Legionella, Uni-Gold C. difficile, and Uni-Gold Syphilis products. The company sells its products through its direct sales force in the United States; and a network of independent distributors and strategic partners internationally. Its customers include public health facilities, hospitals, and other outreach facilities, as well as clinical and reference laboratories. Trinity Biotech plc was founded in 1992 and is headquartered in Bray, Ireland.

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.